# Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies

> **NCT06408194** · PHASE1 · RECRUITING · sponsor: **Stanford University** · enrollment: 20 (estimated)

## Conditions studied

- Leukemia
- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** CD22CART infusion
- **DRUG:** Tisagenlecleucel

## Key facts

- **NCT ID:** NCT06408194
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-13
- **Primary completion:** 2026-07
- **Final completion:** 2026-07
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06408194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06408194, "Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06408194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*